Last $11.50 USD
Change Today -0.05 / -0.43%
Volume 832.9K
MNTA On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 1:19 PM 04/16/14 All times are local (Market data is delayed by at least 15 minutes).

momenta pharmaceuticals inc (MNTA) Snapshot

Open
$11.66
Previous Close
$11.55
Day High
$11.79
Day Low
$11.44
52 Week High
01/9/14 - $19.90
52 Week Low
04/11/14 - $10.24
Market Cap
603.5M
Average Volume 10 Days
1.3M
EPS TTM
$-2.14
Shares Outstanding
52.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MOMENTA PHARMACEUTICALS INC (MNTA)

momenta pharmaceuticals inc (MNTA) Related Businessweek News

No Related Businessweek News Found

momenta pharmaceuticals inc (MNTA) Details

Momenta Pharmaceuticals, Inc., a biotechnology company, is engaged in the structural characterization, process engineering, and biologic systems analysis of complex molecules in the areas of complex generics, biosimilars, and novel drugs. The company’s complex generics programs comprise Enoxaparin sodium injection, a generic version of Lovenox that is used for the prevention and treatment of deep vein thrombosis, and to support the treatment of acute coronary syndromes; and M356, a generic version of Copaxone, which is a glatiramer acetate injection indicated for the reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis. Its biosimilars programs include M923 and M834, which are biosimilars for autoimmune and inflammatory diseases; and M511, a monoclonal antibody for oncology. The company’s novel products comprise M402, a novel oncology drug candidate that is in a Phase 1/2 clinical study, which binds to various growth factors, adhesion molecules, and chemokines to inhibit tumor progression, metastasis, and angiogenesis; and the sialylation technology that is a discovery program of a mixture of human immunoglobulin G antibodies for the treatment of inflammatory diseases. It has collaboration and license agreements with Sandoz AG; Baxter International, Inc.; Baxter Healthcare Corporation; and Baxter Healthcare SA. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.

269 Employees
Last Reported Date: 02/28/14
Founded in 2001

momenta pharmaceuticals inc (MNTA) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $600.0K
Co-Founder, Chief Scientific Officer and Seni...
Total Annual Compensation: $374.4K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $350.2K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $380.5K
Senior Vice President, General Counsel and Co...
Total Annual Compensation: $361.0K
Compensation as of Fiscal Year 2012.

momenta pharmaceuticals inc (MNTA) Key Developments

Momenta Pharmaceuticals Inc. Presents at Boston Biotech BD Boston Conference, Mar-25-2014 through Mar-26-2014

Momenta Pharmaceuticals Inc. Presents at Boston Biotech BD Boston Conference, Mar-25-2014 through Mar-26-2014. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, United States. Presentation Date & Speakers: Mar-25-2014, Rick Shea. Mar-26-2014, Rick Shea.

Momenta Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013

Momenta Pharmaceuticals Inc. reported earnings results for the fourth quarter and full year ended December 31, 2013. The company has reported that net loss for the fourth quarter ended December 31, 2013 was $30.06 million, or $0.59 loss per share, compared to a net loss of $17.68 million, or $0.35 loss per share, for the same quarter ended December 31, 2012. Total collaboration revenue for the fourth quarter ended December 31, 2013 was $12.75 million, compared to $12.73 million for the same quarter ended December 31, 2012. Net loss for the year ended December 31, 2013 was $108.41 million, or $2.13 loss per share, compared to a net loss of $58.65 million, or $1.16 loss per share, for the year ended December 31, 2012. Total collaboration revenue for the year ended December 31, 2013 was $35.46 million, compared to $63.92 million for the year ended December 31, 2012.

Momenta Pharmaceuticals Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013; Provides Earnings Guidance for the Year 2014

Momenta Pharmaceuticals Inc. reported unaudited earnings results for the fourth quarter and full year ended December 31, 2013. For the quarter, the company reported net loss of $30,062,000 or $0.59 per share basic and diluted compared to $17,677,000 or $0.35 per share a year ago. Total collaboration revenue was $12,750,000 compared to $12,728,000 a year ago. Operating loss was $30,336,000 against $18,185,000 a year ago. For the year, the company reported net loss of $108,408,000 or $2.13 per share basic and diluted compared to $58,648,000 or $1.16 per share a year ago. Total collaboration revenue was $35,465,000 compared to $63,921,000 a year ago. Operating loss was $109,591,000 against $60,106,000 a year ago. For the year 2014, the company expects its total operating expenses, excluding stock-based compensation and net of collaborative revenues, are expected to average $30 to $32 million per quarter. The company expects net cash usage, excluding revenue from the potential launch of M356, will average approximately $30 million per quarter, with quarterly cash burn in the second half of 2014 partially offset by an expected $19 million from milestone payments earned under the Baxter collaboration.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MNTA:US $11.50 USD -0.05

MNTA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Eagle Pharmaceuticals Inc/DE $12.13 USD +0.13
Natco Pharma Ltd 706.70 INR -3.55
OraSure Technologies Inc $6.53 USD +0.09
ProPhase Labs Inc $1.87 USD +0.053
Sucampo Pharmaceuticals Inc $6.91 USD +0.085
View Industry Companies
 

Industry Analysis

MNTA

Industry Average

Valuation MNTA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 16.7x
Price/Book 2.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.2x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MOMENTA PHARMACEUTICALS INC, please visit www.momentapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.